Compare AIN & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIN | RAPP |
|---|---|---|
| Founded | 1895 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 1994 | 2024 |
| Metric | AIN | RAPP |
|---|---|---|
| Price | $62.72 | $45.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $60.25 | $48.50 |
| AVG Volume (30 Days) | 255.4K | ★ 302.9K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $1,054,132,000.00 | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $53.75 | ★ N/A |
| Revenue Growth | ★ 7.29 | N/A |
| 52 Week Low | $41.15 | $13.86 |
| 52 Week High | $77.00 | $46.72 |
| Indicator | AIN | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 25.15 | 65.49 |
| Support Level | $53.83 | $33.54 |
| Resistance Level | $64.04 | N/A |
| Average True Range (ATR) | 2.87 | 2.44 |
| MACD | -1.81 | 0.22 |
| Stochastic Oscillator | 14.00 | 94.69 |
Albany International Corp is a textiles and materials processing company specializing in engineered fabrics and composite components and assemblies for the paper, industrial manufacturing and aerospace industries. It operates through two segments: Machine Clothing, which produces custom-designed fabrics and high-speed process belts for paper, paperboard, tissue, towel and pulp, as well as engineered fabrics for other industrial applications, and contributes the majority of revenue; and Albany Engineered Composites, which provides engineered composite parts for the aerospace and defense industries. The company generates revenue from the United States, Switzerland, Brazil, China, Mexico, France and other areas.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.